EFTR实时信号 | 通过Getagraph.com最大化利润

出售 109079 min ago

@ $11.19

发出时间: 13 Feb 2024 @ 23:58

回报率: -83.11%

Live Chart Being Loaded With Signals

Commentary (27 Apr 2024 @ 04:00):

eFFECTOR Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer...

Stats
今日成交量	161 694
平均成交量	382 382
市值	6.97M
EPS	$-3.42 ( 2024-03-27 )
下一个收益日期	( $-2.17 ) 2024-05-14
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.120
ATR14	$0.0120 (0.63%)

Insider Trading

Date	Person	Action	Amount	type
2024-02-19	Loewy Caroline M	Buy	2 000	Stock Option (Right to Buy)
2024-02-19	Bhatt Elizabeth	Buy	2 000	Stock Option (Right to Buy)
2024-02-19	Ehrlich Christopher B	Buy	2 000	Stock Option (Right to Buy)
2024-02-19	Klencke Barbara	Buy	2 000	Stock Option (Right to Buy)
2024-02-19	Harrington-smith Kristen	Buy	2 000	Stock Option (Right to Buy)

INSIDER POWER
45.06
Last 95 transactions
Buy: 5 541 401 \| Sell: 1 016 887

音量相关性

長: -0.09 (neutral)

短: -0.54 (weak negative)

Signal:(48.371) Neutral

eFFECTOR Therapeutics, 相关性

10 最正相关
APOP	0.91
FLGT	0.875
PIII	0.875
PRSR	0.871
MAGS	0.871
SOFIW	0.867
CMLF	0.867
LPTX	0.864
AGCUU	0.863
WKSP	0.863

10 最负相关
ULTA	-0.855
IEP	-0.845
TNDM	-0.833
IART	-0.83
ASO	-0.829
CDAK	-0.828
IQ	-0.827
PAYS	-0.827
SBNYP	-0.817
PHCF	-0.815

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

eFFECTOR Therapeutics, 相关性 - 货币/商品

-0.04
( neutral )

0.15
( neutral )

0.00
( neutral )

0.09
( neutral )

0.60
( weak )

-0.16
( neutral )

eFFECTOR Therapeutics, 财务报表

Annual	2023
营收:	$0
毛利润:	$-111 000 (0.00 %)
EPS:	$-16.37

FY	2023
营收:	$0
毛利润:	$-111 000 (0.00 %)
EPS:	$-16.37

FY	2022
营收:	$3.55M
毛利润:	$3.50M (98.51 %)
EPS:	$-7.85

FY	2021
营收:	$0.00
毛利润:	$0.00 (0.00 %)
EPS:	$1.050

Financial Reports:

No articles found.

eFFECTOR Therapeutics,

eFFECTOR Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer. Its lead product candidate is Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer. The company is also developing Zotatifin, a small molecule designed to inhibit eukaryotic initiation factor 4A (eIF4E), which is in phase 2clinical trial to treat patients with solid tumors. It has a collaboration agreement with Pfizer Inc. to develop inhibitors of eIF4E. eFFECTOR Therapeutics, Inc. was founded in 2012 and is headquartered in Solana Beach, California.